H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

March 13, 2026 6:10 AM

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $23.00 price target on Candel Therapeutics Inc. (NASDAQ: CADL).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found